Member Info for crumbs

Dale that is a very true point and been the holding back of Lindy achieving all she may have by now... she was never properly backed even when her novel scientific immunotheraphy approaches were showing curative affect in human trial... there is that young lady from the mannny years ago Daily Mail article who responded so well to I think a prototype ImmunoBody.... look how far that platform has come now but wonder how much further and faster with the right money backing.... Calculus and the other UK VCTs have been very good and loyal but they just could never invest the amount really needed... CRUK over the years has sponsored her work (MAbs development)but again just not enough considering the need to get products into trials it took Redmile and their American approach to see the problem and the solution and the huge potential therewithin..... Scancell has over all these years built a pipeline that could indeed sustain a large pharma if the products prove clinical worth.... Again though buyouts are possible to me the direction does look to go from being a current Poundland BioNTech to a BioNTech peer the way to achieve that seems clear to me too and that is to get as much into trials as possible build lots of validating data seal proper partnerships with solid pharma partners possibly BioNTech themselves... move beyond AIM - NASDAQ listing and let Lindy do what she does she is a great talent spotter and tech server she could be what the UK needs build a UK biotech that does take fantastic research all the way!

BTW I said before we now have one product in an actual trial it is two when we consider Avidimab is now a part of the next-gen ImmunoBodies ... Hope to hear a lot more about Zacari and plans for that at AGM it is a very interesting added angle to Scancells potential with licensing that tech out considering the massive value and importance of the MaB market.

Hah flow. its ok TF think I sent it before finishing :).. Just pointing out though current sp stasis can seem boring or frustrating it is far better than it was and also it is not quite the true picture as now things real things are actually happening..... even bringing the sorry failed sage of SCIB1 combo trial to a conclusion will be something... but at last, we have one product with massive potential in trial and soon another and by this time next year possibly a few more....

cont ... that did not get much further than lab science and presentations and the one trial we did have we never got rewarded for its success... Now we are an Oxford Biotech with labs and the ability to push great science through into clinical products.. We are in the Covid race a market of over $120 billion per annum worth and our product in the race could just be special enough to make a big difference and it is currently in trial and generating data! No trial stoppage so far ... moditope is complete game-changer potential beyond what most here even imagine... and that is now going into the trial as the challenges have been overcome and the funds are there and even modi2 is going to be trial ready.... the MaBs and Avidimab offer another sphere of opportunity that few can fully comprehend we are talking a market again in the hundreds of Billions.... Avidimab offers blockbuster MaBs even more chance of commerical life etc.... so... Relax lol

Sometimes it is worth remembering well for us LTHs it is an all too real and recent enough memory but Scancell was a share that kept on going down down down from its momentary moditope discovery RNS 60p or whatever high to the AGM of doom and then the years of SCIB1 combo trial going nowhere then the real-world challenges of turning the great discovery of moditope into an actual clinical product all costing never enough to achieve everything available money that was raised by ever more dilution..... The coming in of Vulpes and then especially Redmile changed that completely and from guessing where below 10p we were going to be.... 3p happened ! now most of us are in profit and the sp has stablised arond its ii support.... but more importantly, the work is being done the company is not the same one it was it is not the Notts uni spinout with great novel innovative science that

Relax is indeed the key word as we all know Redmile have a plan and it is to make a shed load of money from backing Lindys science through to data and that is exactly what they have done and continued to do the whole MaBs situation of no need for a low ball deal/s and data likely before any deal concluded also them buying a few more at 20p is clear evidence is them basically giving Lindy a backing bonus... they are supporting all the pipeline through to value adding data beciause only one product success can mean many multiples of their initial investment.... obs how they then intend to exit is open to debate I'm pretty sure with data added value they would take on to NASDAQ with a whopping IPO .... Also It seems clear to me Lindy wants to keep control of her babies for as long as possible so I do not see any 'takeovers' in the offing she said it herself the plan is a 'sustainable' business to me it sounds like she wants to be in the happy place Sahin is in.... have her own big bio...

Thats the science of modi 2 getting an airing and then at this one in Sept https://www.euromabnet.com/meeting/11th-meeting-online.php Lindy is an invited Speaker and first off doing 30 minutes on AvidiMab....

I like to cut n paste my jammy butties :)

I thought it wad jam tomorrow :)

It once again shows ii support and that both Vulpes and Redmile see 20p+ as a current fair value for Scancell ... It is more a market reassurance as AIM is very twitchy

'In a statement, IronRidge said lead manager and underwriter, Canaccord will fully underwrite the Ricca rights issue, which enables the company to fast-track the demerger by almost one month.

Completion of the demerger and distribution of the rights issue shares is now expected to take place on 22 December 2021. Completion had originally been anticipated on 18 January 2022.

"Canaccord's commitment allows us to fast-track the demerger in preparation for a fresh start to activity on the ground in 2022,” said IronRidge chief executive officer Vincent Mascolo.

“Significant opportunities exist for Ricca across a broad portfolio of West African gold projects as the precious metals complex looks to be entering a new phase of growth. We believe that Ricca offers a new and exciting separate investment opportunity for IronRidge shareholders to capitalise upon this growth.”

IronRidge will not retain any interest in Ricca following the proposed transaction.

Post the proposed demerger, IronRidge will maintain a strong cash position of around US$22mln.'
https://www.proactiveinvestors.co.uk/companies/news/964958/ironridge-to-fast-track-gold-demerger-after-canaccord-agrees-to-fully-underwrite-rights-issue-964958.html

The gift that keeps giving .... once again the sub 20p trade is a winner :) ... better to be in a 'sustainable' bio tech me thinks :)

Berm yes that would make sense and I reckon would be well received by market.

Me either lol.... I suppose in signing up to partake they obviously agree to two doses I think so long as no bad reaction to first... and I did with my Astra one! then they should be fine to take to second especially considering the pandemic situation on SA...Again I'd expect Sally to give more info about the trial at AGM...

Today is with our buddies ..... Be interesting to see how that plays out ...far better to secure real solid deal/s IMHO and that is what Lindy is pursuing :)

Fast track to freebies :) if someone can bash down sp to 16p, please do!

I'd doubt we get an update for 2nd dosing but certainly significant for us can only hope those second doses are taken up and indeed a significant number of first doses have been too hopefully that is something Sally will share at AGM... Looks like safety-wise there are no significant issues as expected as trial is ongoing so... onwards to data ...Which those second doses ought to bring in :)

There is a whole lot of potential value in that for those that understand what that means and the greatest thing.... what was confined to research is now transitioning into the clinic ....... patent landgrab backed :)

Hasibos I think you will find these proactive interviews are basically given the question to ask by the Companies being interviewed this is just the current RNS in video form (always nice to see)... We know that the plan is to prove up Covidity in a ph1/2 and partner for a ph3 and onwards...Lindy s hardly going to tell you who she is talking to and what they are all saying you get that once a deal is done whether that is CEPI a pharma more GOV funds... or indeed Covidity gets shelved , reckon more will be shared at AGM

I miss Cliff ........ lol no not really! Lindy looking very Father Christmasy there..... Delivering all the gifts :) sounds like lots of trials on their way.

Berm simples! :) one day its bricks and mortar the next its wet cardboard

Johnny, I'm glad the rumours of you drowning in Coronation Streets sewers were fake news... Drowning in the Rovers may hold some truth though:)

The Diggle Wiggles has been much talked of here and yeah they managed to keep sp from breaking 30p and also from sinking below 20p whether that was deliberate or not or if it will continue who knows!